Cheung K L
Department of Surgery, The University of Hong Kong, Queen Mary Hospital and Tung Wah Hospital.
Aust N Z J Surg. 1999 Jul;69(7):492-4. doi: 10.1046/j.1440-1622.1999.01609.x.
In most Western countries gamolenic acid is the first-line treatment for women with cyclical mastalgia.
A prospective study was carried out in the breast referral clinic of the Department of Surgery, University of Hong Kong to evaluate the treatment of cyclical mastalgia using gamolenic acid provided in evening primrose oil (Efamast, Scotia Pharmaceuticals Ltd, Scotia House, Stirling, Scotland) as a pioneer experience in Asia. In addition, the features of cyclical mastalgia in Oriental women were studied by conducting a survey using anonymous questionnaires.
Sixty-six women with disturbing cyclical mastalgia seen by one breast surgeon were followed up with a breast pain diary. Thirty-four women had persistently disturbing mastalgia and were commenced on Efamast. Responses were measured at 3 and 6 months according to a standardized protocol. An overall useful response rate of 97% was observed at 6 months. Side-effects were found in 12% but all were insignificant.
Efamast may be recommended as a first-line specific treatment for Oriental women with disturbing cyclical mastalgia.
在大多数西方国家，γ-亚麻酸是治疗周期性乳腺疼痛女性的一线药物。
在香港大学外科学系乳腺转诊诊所开展了一项前瞻性研究，以评估使用月见草油中提供的γ-亚麻酸（Efamast，苏格兰斯特灵市斯科舍制药有限公司斯科舍大厦）治疗周期性乳腺疼痛的效果，这在亚洲是一次开创性的尝试。此外，通过使用匿名问卷进行调查，研究了东方女性周期性乳腺疼痛的特征。
一位乳腺外科医生诊治的66例患有令人困扰的周期性乳腺疼痛的女性，采用乳腺疼痛日记进行随访。34例女性持续存在令人困扰的乳腺疼痛，并开始服用Efamast。根据标准化方案在3个月和6个月时测量疗效。6个月时观察到总体有效率为97%。发现12%的患者有副作用，但均不严重。
对于患有令人困扰的周期性乳腺疼痛的东方女性，Efamast可被推荐作为一线特异性治疗药物。
Zotero 插件